WallStSmart

Bioventus Inc (BVS)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 6352% more annual revenue ($37.54B vs $581.85M). MDT leads profitability with a 13.9% profit margin vs 9.4%. BVS appears more attractively valued with a PEG of 1.53. MDT earns a higher WallStSmart Score of 68/100 (B-).

BVS

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 6.5Value: 5.7Quality: 4.5
Piotroski: 5/9Altman Z: 0.90

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BVS.

MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$90.96

$3.47 discount

UndervaluedFair: $94.43Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BVS3 strengths · Avg: 9.0/10
EPS GrowthGrowth
327.3%10/10

Earnings expanding 327.3% YoY

Return on EquityProfitability
23.9%9/10

Every $100 of equity generates 24 in profit

P/E RatioValuation
16.6x8/10

Attractively priced relative to earnings

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

Areas to Watch

BVS4 concerns · Avg: 3.5/10
PEG RatioValuation
1.534/10

Expensive relative to growth rate

Revenue GrowthGrowth
3.8%4/10

3.8% revenue growth

Market CapQuality
$886.60M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.163/10

Elevated debt levels

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BVS

The strongest argument for BVS centers on EPS Growth, Return on Equity, P/E Ratio.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bear Case : BVS

The primary concerns for BVS are PEG Ratio, Revenue Growth, Market Cap.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

BVS carries more volatility with a beta of 0.65 — expect wider price swings.

MDT is growing revenue faster at 13.7% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDT scores higher overall (68/100 vs 62/100) and 13.7% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bioventus Inc

HEALTHCARE · MEDICAL DEVICES · USA

Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?